药学前沿大讲堂第112讲-Prolyl peptidyl isomerases (PPIs) in proteoglycan synthesis and atherosclerosis
Prolyl peptidyl isomerases (PPIs) in proteoglycan synthesis and atherosclerosis
题 目：Prolyl peptidyl isomerases (PPIs) in proteoglycan synthesis and atherosclerosis
报告人：Professor Peter J. Little
Foundation Head, Discipline of Pharmacy and Group Leader
Diabetes Complications Group, Health Innovations Research Institute
RMIT University
主持人：郑文华教授
bm11222宝马娱乐网站
时 间：2012年3月19日（周一）下午15：00～16：00
地 点：中山大学东校区bm11222宝马娱乐网站 112会议室
Atherosclerosis is the chronic inflammatory pathological process that underlies most cardiovascular disease which is the largest single cause of premature mortality in developed and now developing countries. TGF-β is well-recognised as having a key role in the development of atherosclerosis and consequently of cardiovascular disease. Smad linker region phosphorylation is an important signalling pathway in TGF-β mediated proteoglcyan synthesis. Pin 1 binds to phosphorylated residues in the linker region of Smad2 where it can regulate the function of the Smad as a transcription factor. Pin1 is a critical downstream signalling component in TGFβ-mediated proteoglycan and glycosaminoglycan chain hyperelongation in vascular smooth muscle cells.
报告人简介：
Peter J Little教授是世界知名的药学家，目前就职于澳大利亚皇家墨尔本理工大学(RMIT University)，药学学科带头人，糖尿病并发症课题组组长，现担任澳大利亚生物脉管学会会长，澳大利亚Monash University荣誉教授，他致力于促进心脏科学心血管药物研究等方面的发展,为此作出了重要贡献并在澳大利亚及世界上获得多种奖项。撰写多篇高影响因子的论文发表于circulation, J. Biol Chem， Cell Mol Life Sci, J. Cell Mol Med，Atherosclerosis, Curr.Opin Lipidol等高水平杂志上，已发表120多篇高水平论文，论文被引用3000余次，现担任“nutrition”等多家国际知名杂志编辑和审稿人。
